Press Release|Articles|January 7, 2025

Camber Pharmaceuticals Announces Addition of Bortezomib for Injection

Bortezomib for Injection is a proteasome inhibitor indicated for treatment of adult patients with multiple myeloma and treatment of adult patients with mantle cell lymphoma.

Camber Pharmaceuticals is excited to announce the addition of Bortezomib for Injection.

Bortezomib for Injection is a proteasome inhibitor indicated for:

  • treatment of adult patients with multiple myeloma
  • treatment of adult patients with mantle cell lymphoma

Bortezomib for Injection is available in 3.5 mg strength, packaged in a single-dose vial.

To find out more information on Bortezomib for Injection please visit: www.camberpharma.com/bortezomib

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME